Literature DB >> 21044442

Perioperative use of methotrexate.

F Heldmann1, J Braun.   

Abstract

Methotrexate (MTX) is the disease modifying antirheumatic 'anchor' drug for the treatment of patients with rheumatoid arthritis (RA). Despite its widespread use and the frequent need of elective orthopaedic and other types of surgical procedures in patients with RA, some confusion exists concerning the use of MTX in the perioperative period. Currently available data do not suggest a need to discontinue MTX because of surgery. There is some evidence that treatment with MTX is safe prior to and after elective surgical procedures. Importantly, disease activity is better controlled when MTX is not interrupted from weekly administration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044442

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

Review 1.  Inflammatory bowel disease: perioperative pharmacological considerations.

Authors:  Ajay Kumar; Moises Auron; Ashish Aneja; Franziska Mohr; Alok Jain; Bo Shen
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

2.  Lymphoproliferative disorder with pathological fracture of the femur in a patient with rheumatoid arthritis treated with methotrexate: A case report.

Authors:  Naoto Oebisu; Manabu Hoshi; Makoto Ieguchi; Tadashi Iwai; Sayaka Tanaka; Masahiko Osawa; Hiroaki Nakamura
Journal:  Mol Clin Oncol       Date:  2018-06-14

3.  Short time administration of antirheumatic drugs - methotrexate as a strong inhibitor of osteoblast's proliferation in vitro.

Authors:  Tobias Annussek; Johannes Kleinheinz; Szuwart Thomas; Ulrich Joos; Kai Wermker
Journal:  Head Face Med       Date:  2012-09-29       Impact factor: 2.151

4.  Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era".

Authors:  Amy L Lightner; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-04-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.